Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Invested Capital (2016 - 2025)

Lipocine's Invested Capital history spans 14 years, with the latest figure at $14.1 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 26.02% year-over-year to $14.1 million; the TTM value through Sep 2025 reached $14.1 million, down 26.02%, while the annual FY2024 figure was $21.0 million, 3.08% up from the prior year.
  • Invested Capital reached $14.1 million in Q3 2025 per LPCN's latest filing, down from $17.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $47.2 million in Q4 2021 to a low of $14.1 million in Q3 2025.
  • Average Invested Capital over 5 years is $29.7 million, with a median of $28.6 million recorded in 2023.
  • Peak YoY movement for Invested Capital: surged 456.3% in 2021, then tumbled 42.84% in 2023.
  • A 5-year view of Invested Capital shows it stood at $47.2 million in 2021, then dropped by 24.56% to $35.6 million in 2022, then crashed by 42.84% to $20.4 million in 2023, then rose by 3.08% to $21.0 million in 2024, then crashed by 32.65% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Invested Capital are $14.1 million (Q3 2025), $17.1 million (Q2 2025), and $19.2 million (Q1 2025).